Larimar Therapeutics Inc

Healthcare · Biotechnology

2.80$ -1.1% vs. previous close Closing price · As of: Oct 7, 2026

Statements

Balance Sheet

Larimar Therapeutics Inc (LRMR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 165 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet LRMR
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	143	132	119	109	96	106	93	80	132	122	110	104	93	5.2	0.0	125	114	105	93	81	88	79	71	63	133	126	119	112	104	96	248	237	219	200	170	150	187	146	209	165
Current Assets	142	131	119	108	96	105	91	78	131	121	4.4	94	83	4.8	0.0	119	108	98	86	74	81	72	65	57	127	121	113	106	98	90	231	231	213	195	165	146	183	142	205	161
Cash	25	32	29	32	19	41	46	41	45	49	-4.4	37	43	1.0	0.0	113	101	68	62	71	72	70	63	20	86	27	112	94	39	27	110	32	35	33	21	21	90	85	178	93
Cash & Short-Term Investments	139	129	117	106	93	102	89	76	128	118	4.4	92	82	1.0	0.0	114	102	93	81	71	78	70	63	55	125	118	112	104	96	87	227	226	204	183	158	139	175	137	200	156
Receivables	–	–	–	–	–	–	–	–	–	–	1.6	1.5	0.2	0.2	0.2	0.1	0.0	0.0	0.1	0.1	0.2	0.2	0.3	0.2	0.1	–	0.3	0.3	–	0.3	1.1	0.8	0.9	1.1	1.1	1.0	1.0	0.7	0.8	0.3
Inventory	–	–	–	–	–	–	–	–	–	–	-2.8	–	–	3.2	-0.2	-0.1	0.0	0.0	–	–	–	-0.2	–	–	–	–	-0.3	-0.3	–	–	–	–	-0.9	–	–	–	–	–	–	–
Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	–	1.2	8.3	8.1	7.9	0.8	4.9	4.7	5.0	4.8	4.9	1.1	4.5	4.3	4.1	3.9	0.8	0.8	3.3	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	13	9.9	8.6	9.2	7.0	27	28	28	28	28	28	32	33	5.9	0.0	13	11	15	14	13	16	14	14	13	14	16	13	12	11	14	17	26	21	28	26	30	48	68	50	38
Current Liabilities	11	9.9	8.6	9.2	7.0	7.3	7.5	9.3	11	13	14	13	16	5.9	0.0	6.6	5.2	9.0	8.4	7.7	10	8.8	8.9	7.7	9.4	11	8.0	7.3	6.6	9.5	13	21	16	24	22	27	45	65	48	34
Short-Term Debt	3.1	3.6	2.8	2.1	1.3	–	–	1.8	3.6	5.5	7.3	7.9	7.7	0.1	7.7	0.6	0.5	0.5	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.7	0.8	0.8	1.0	1.0	1.1	1.1	1.1	1.2	1.1	1.1	1.2
Accounts Payable	3.6	2.6	1.9	4.4	2.7	3.0	3.8	3.0	2.6	3.6	3.2	2.1	3.3	3.5	0.0	2.3	1.3	2.6	3.2	1.5	1.8	1.7	2.4	0.4	0.8	1.7	0.7	2.3	0.8	1.3	1.9	2.9	1.7	2.4	2.3	4.2	11	5.2	8.6	7.6
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	14	12	10	8.5	6.7	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	130	122	111	100	89	78	65	52	104	93	2.9	72	60	-0.7	0.0	113	103	90	79	68	72	64	57	50	119	111	106	100	93	82	231	211	198	172	144	120	139	78	158	127
Retained Earnings	-227	-238	-251	-264	-276	-290	-306	-321	-336	-351	-364	-376	-389	-23	0.0	-41	-51	-66	-78	-90	-107	-116	-125	-134	-142	-152	-158	-166	-176	-189	-203	-225	-240	-269	-298	-325	-372	-435	-464	-497
Shares Outstanding	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8	3.7	3.2	3.1	9.2	9.2	3.1	9.2	9.4	16	16	16	16	18	18	18	18	22	24	44	44	44	44	54	64	64	64	64	64	78	85	85	104

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings